Final Thoughts and Future Innovations

Panelists discuss how ongoing advances in newly diagnosed multiple myeloma (NDMM) therapy are transforming patient outcomes through precision-based treatment, sustained minimal residual disease (MRD) suppression, and better quality of life. They foresee a continued shift toward tailored therapy durations guided by MRD results and patient-specific biology. The discussion highlights innovations such as bispecific antibodies, chimeric antigen receptor T-cell therapy, and targeted maintenance approaches, predicting these will further extend remission durability and reduce relapse rates.